Monday, April 19, 2010 8:18:49 AM
BOTHELL, WA -- (Marketwire)
04/19/10
MDRNA, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Intellectual Property Office of New Zealand (IPONZ) has issued a Notice of Acceptance for patent application 553828, titled "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid." Allowed claims cover small interfering RNAs (siRNA) directed against the tumor necrosis factor (TNF) gene as well as several of the Company's key nucleic acid condensing and delivery peptide motifs in combination with a siRNA directed against TNF. This patent application was filed in 2005 as part of MDRNA's global intellectual property strategy which comprises a broad comprehensive patent portfolio protecting the Company's proprietary siRNA constructs, nucleic acid chemistry, nucleic acid delivery platforms, and its extensive library of siRNAs directed against therapeutic targets.
"The TNF family of cytokines includes some of the most validated targets in drug development and the ability to inhibit a specific member such as TNF-alpha remains a key therapeutic approach for many diseases," stated Barry Polisky, Chief Scientific Officer of MDRNA. "Highly potent siRNAs that inhibit TNF may have direct application in the treatment of inflammatory bowel disease, rheumatoid arthritis, psoriasis and other inflammatory conditions. Efficient delivery to specific cell types involved in these diseases is critical and the peptides protected under this patent provide a basis upon which we can modify our DiLA2 technology to specifically target TNF producing cells."
TNF-alpha (TNF-a) is the most studied member of the TNF family of cytokines. First described as a factor that causes necrosis (death) of tumor cells, subsequent research revealed TNF-a plays a key role within the immune system. TNF-a is produced by cells in blood and most tissues, and virtually all cells respond to TNF-a. It is the role that TNF-a plays in mediating chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, that has been the focus of drug development efforts. Besides attaining blockbuster status in the treatment of rheumatoid arthritis, TNF inhibitors (e.g., Enbrel® and Remicade®) have revealed a potential role in multiple diseases. The ability to deliver a TNF-a siRNA to specific cells involved in inflammatory diseases and cancer provides a unique opportunity for an RNAi-based therapeutic.
"One of our main objectives in building an industry-leading RNAi company is to develop a patent portfolio that is both comprehensive and distinct from other RNAi companies," stated Mark Bales, Ph.D., Intellectual Property Counsel at MDRNA. "We believe this allowance demonstrates that MDRNA has a leading position in the field of RNAi therapeutics and that it is an excellent addition to our growing patent estate. We expect to receive additional similar allowances globally that will expand the breadth of our patent estate and further distinguish MDRNA as a leader in the RNAi field."
About MDRNA's Technology
MDRNA has a broad intellectual property estate that encompasses four key RNAi technology platforms: siRNA constructs, chemistry, nucleic acid delivery, and gene targets. The MDRNA-owned siRNA constructs and chemistry include its proprietary UsiRNA construct, which is a duplex siRNA chemically modified with non-nucleotide acyclic monomers (UNAs), and is distinct from the standard siRNA construct used by others in the industry. UsiRNAs are fully recognized by the RNAi machinery and provide for potent RNAi activity while specific placement of UNAs in a duplex siRNA minimizes potential off-target effects by the guide strand and reduces undesired passenger strand activity. Furthermore, UsiRNAs escape the surveillance mechanisms associated with cytokine induction, and provide protection from nuclease degradation.
The MDRNA delivery platforms include DiLA2 and nanoparticle forming peptides. DiLA2 is an MDRNA proprietary delivery platform of novel synthetic di-alklylated amino acid compounds used to make liposomal delivery formulations. The DiLA2 platform enables MDRNA to tailor the charge, linker and acyl chains of amino acids in order to configure liposomes for delivery to target tissues of interest. In addition, the platform is designed to permit attachment of various peptides and other targeting molecules to improve a variety of delivery characteristics. The MDRNA peptide nanoparticle platform includes exclusively in-licensed and developed IP surrounding the use of peptides for nanoparticle formulations that increase cellular uptake and endosomal release of siRNAs. MDRNA is currently biopanning its patented phage display library to identify additional peptides for targeted delivery, cellular uptake and endosomal release of siRNA.
MDRNA owns or controls 17 issued or allowed patents, and has 36 pending patent applications, 125 pending foreign patent applications and 7 PCT applications.
Recent ATRX News
- Form SEC STAFF ACTION - SEC Staff Action: ORDER • Edgar (US Regulatory) • 01/30/2024 09:00:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 09:25:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 09:01:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:01:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:51:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:35:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 08:58:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 07:32:22 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/15/2023 08:05:13 PM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM